Sign in to continue:

Thursday, February 26th, 2026

Ziff Davis, Inc. 8-K SEC Filing Summary for February 26, 2026 – Company Details and Disclosure Information

Ziff Davis, Inc. Files 8-K: Participation in Susquehanna 15th Annual Technology Conference

Key Points:

  • Ziff Davis, Inc. (NASDAQ: ZD) has filed a Form 8-K with the SEC, announcing its participation in the Susquehanna 15th Annual Technology Conference, dated February 26, 2026.
  • No webcast will be available for the conference, meaning information shared at the event will not be publicly broadcast.
  • The filing is made under Item 7.01: Regulation FD Disclosure, which covers the dissemination of material information to investors and the market.
  • The filing was signed by Jeremy Rossen, Executive Vice President, General Counsel and Secretary of Ziff Davis, Inc.

Important Details for Shareholders and Potential Market Impact:

  • Conference Participation: The company’s appearance at a major technology investor conference could be significant, as such events are often used to discuss business strategy, outlook, and recent performance. However, Ziff Davis has not indicated that any material non-public information will be disclosed.
  • No Webcast: The lack of a webcast means that only attendees will hear any comments made by management. This increases the risk that information shared could reach investors indirectly or unevenly, which may lead to market speculation.
  • Regulation FD Compliance: By filing the 8-K, Ziff Davis is signaling its intent to comply with fair disclosure rules. If any material information is shared at the conference, the company would be obligated to disclose it publicly. Investors should monitor for follow-up disclosures or press releases.
  • Corporate Identity: The filing confirms Ziff Davis, Inc. as a Delaware corporation, trading under the symbol ZD on the NASDAQ Stock Market, with its principal executive office at 360 Park Ave South, 17th Floor, New York, NY 10010.
  • Emerging Growth Company Status: Ziff Davis is not an emerging growth company, indicating it is subject to full SEC reporting requirements and accounting standards.
  • Security Details: The company’s common stock, \$0.01 par value, is registered under Section 12(b) of the Exchange Act.

Potential Price-Sensitive Factors:

  • Information Asymmetry: Because management may discuss strategy, outlook, or performance with conference attendees, but no webcast is available, there is a risk that information could move the share price if it leaks or is later disclosed.
  • Regulation FD Disclosure: Investors should be alert for any subsequent filings or press releases, as the company is required to promptly disclose any material information shared at the conference.

Summary:

Ziff Davis, Inc. has made investors aware of its participation in a significant technology conference. While no webcast is available and no specific material disclosures are announced, the event could be an opportunity for the company to communicate with investors and analysts. Shareholders should remain attentive to any follow-up disclosures that may affect the share price. The filing also confirms key details about the company’s registration and reporting status.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. The information herein is based on the latest SEC filing and public data as of the date indicated. No assurance can be given as to future disclosures or market impact.

View ZIFF DAVIS, INC. Historical chart here



Enova International, Inc. 2025 Annual Report: 10-K Filing, Financials, Risk Factors, and Company Overview

Enova International, Inc. 2025 Annual Report: Key Highlights for Investors Enova International, Inc. Files 2025 Annual Report: Key Takeaways for Investors Enova International, Inc. (NYSE: ENVA) has filed its Form 10-K annual report for...

Axsome Therapeutics, Inc. Annual Report 2024: Innovative CNS Medicines, FDA Approvals, Pipeline, and Competitive Landscape

Axsome Therapeutics, Inc. 2025 Annual Report – Key Highlights for Investors Axsome Therapeutics, Inc. (AXSM) 2025 Annual Report – Investor Insights Overview Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company headquartered at One...

T-REX Acquisition Corp. (TRXA) 10-Q Report December 31, 2025: Financial Statements, Mining Revenue, and Key Disclosures

T-REX Acquisition Corp. (TRXA) Reports December 2025 Quarterly Results: Key Highlights and Critical Investor Insights PLANTATION, FL – T-REX Acquisition Corp. (“TRXA” or the “Company”) has released its unaudited consolidated financial statements for the...

   Ad